My research is in nucleic acid chemistry, DNA sequence recognition and application of nucleic acids to nanotechnology, diagnostics and biology. It has produced 300 publications, several patents and 3 start-up companies.
High throughput technology has supported a scientific revolution both in molecular biology and clinical research.
The work of the Bioinformatics Core is balanced between collaborative research with investigators in the Department of Oncology and some independent research funded by external grants.
The goal of the Radiopharmaceuticals and Molecular Imaging group is the development of novel radiopharmaceuticals for the imaging of cancer.
Dr D'Angiolella's group focuses on the identification of new mechanisms governing cell cycle events and the response to genotoxic stress with a particular emphasis on the role of ubiquitin–mediated proteolysis in the process.
Our long-term goal is to study the proteins and mechanisms involved in the coordination and regulation of base excision repair, to unravel their role in the repair of radiation induced DNA damage and to examine the relationship to human diseases, such as cancer.
The focus of my lab is the DNA damage response to the tumour micro-environment.
The aim of my research is to maximise clinical benefit in terms of better tumour control and reduction in toxicity
Our group undertakes both laboratory and clinical research that aims to better understand the molecular basis of tumour cell resistance to radiation treatment with the long term aim of developing treatments to make radiotherapy more effective.
The Radiation Biophysics Core provides radiation resources and expertise in addition to the development and use of novel radiation sources and techniques.
Understanding how genome stability is maintained in response to DNA double-strand breaks.
The focus of my lab is the investigation of DNA damage signalling and DNA repair as they relate to the aetiology of bladder cancer and its response to radiotherapy and combined modality treatments.
Professor Maughan will lead the Clinical Research Programme at the CRUK/MRC Oxford Institute for Radiation Oncology, aiming to deliver a step change in the effectiveness of radiotherapy through the evaluation of novel scientific approaches derived from the Institute's scientists in hypothesis driven clinical trials. In addition he aims to identify means to select patients for appropriate therapy through the use of functional imaging and biomarkers.
The effects of radiation on cancer cells and on mechanisms of resistance to radiation with the goal of sensitizing cells to radiation by blocking mechanisms that control cell survival.
Research group interested in the mechanisms underlying the development of metastasis.
The main areas of interest in our lab are cell signalling and stem cells and cancer stem-like cells.
Focuses on how clusters of DNA damage, formed by ionising radiation, detrimentally interfer with the maintenance of genome stability.
The ultimate goal of my team is to harness technical advances in both medical imaging and radiation delivery to provide improved radiotherapy for individual patients.
The research focus of the group is to understand the role of the ubiquitin-proteasome system (UPS) and its central component p97/VCP in genome stability and consequently in cancer and ageing.
The focus of the group is to translate advances in our understanding of the molecular pathology of lung cancer and its microenvironment into better treatments for patients.
Translation of biochemical knowledge of DNA adducts and excision repair to the prevention and treatment of cancer.
Imaging the microenvironment in brain metastasis
The Bioanalysis Core aims to provide support in two main areas, determination of concentrations of small molecules, both of experimental drugs and normal metabolites, using high performance liquid chromatography (HPLC), and Flow Cytometry, used for a diverse array of biomarkers.
How homologous recombination (HR), the major error-free pathway for DNA repair in mammalian cells, regulates telomeres and acts to prevent genomic instability, the underlying mechanism of many cancers.
Development of novel anti-cancer radiopharmaceuticals.
Development of instrumentation to address specific biological hypotheses, primarily involving imaging and image processing.